Cargando…

HE4 as a Biomarker for Endometrial Cancer

SIMPLE SUMMARY: There are currently no blood biomarkers approved for routine clinical use in endometrial cancer. Serum human epididymis protein 4 (HE4) is significantly higher in patients with endometrial cancer compared to patients without endometrial cancer and is associated with a poorer prognosi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Behrouzi, Roya, Barr, Chloe E., Crosbie, Emma J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507549/ https://www.ncbi.nlm.nih.gov/pubmed/34638250 http://dx.doi.org/10.3390/cancers13194764

Ejemplares similares

Serum CA125 and HE4 as Biomarkers for the Detection of Endometrial Cancer and Associated High-Risk Features
por: Barr, Chloe E., et al.
Publicado: (2022)

Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer
por: Behrouzi, Roya, et al.
Publicado: (2020)

Urine CA125 and HE4 for the Triage of Symptomatic Women with Suspected Endometrial Cancer
por: Njoku, Kelechi, et al.
Publicado: (2022)

Current and Emerging Prognostic Biomarkers in Endometrial Cancer
por: Njoku, Kelechi, et al.
Publicado: (2022)

Urine CA125 and HE4 for the Detection of Ovarian Cancer in Symptomatic Women
por: Barr, Chloe E., et al.
Publicado: (2023)

Comparison of two immunoassays for the measurement of serum HE4 for ovarian cancer
por: Barr, Chloe E., et al.
Publicado: (2021)

Urinary Biomarkers and Their Potential for the Non-Invasive Detection of Endometrial Cancer
por: Njoku, Kelechi, et al.
Publicado: (2020)

Proteomic Biomarkers for the Detection of Endometrial Cancer
por: Njoku, Kelechi, et al.
Publicado: (2019)

The Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population
por: Barr, Chloe E., et al.
Publicado: (2022)

Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer
por: Njoku, Kelechi, et al.
Publicado: (2020)

Pre-treatment inflammatory parameters predict survival from endometrial cancer: A prospective database analysis
por: Njoku, Kelechi, et al.
Publicado: (2022)

Impact of pre-treatment prognostic nutritional index and the haemoglobin, albumin, lymphocyte and platelet (HALP) score on endometrial cancer survival: A prospective database analysis
por: Njoku, Kelechi, et al.
Publicado: (2022)

Urinary biomarkers for the detection of ovarian cancer: a systematic review
por: Owens, Gemma L, et al.
Publicado: (2022)

DEveloping Tests for Endometrial Cancer deTection (DETECT): protocol for a diagnostic accuracy study of urine and vaginal samples for the detection of endometrial cancer by cytology in women with postmenopausal bleeding
por: Jones, Eleanor R, et al.
Publicado: (2021)

Expression of HE4 in Endometrial Cancer and Its Clinical Significance
por: Li, Xiao, et al.
Publicado: (2015)

Metabolomic Biomarkers for the Detection of Obesity-Driven Endometrial Cancer
por: Njoku, Kelechi, et al.
Publicado: (2021)

Does Clinical and Biochemical Thyroid Dysfunction Impact on Endometrial Cancer Survival Outcomes? A Prospective Database Study
por: Barr, Chloe E., et al.
Publicado: (2021)

Corrigendum to “Expression of HE4 in Endometrial Cancer and Its Clinical Significance”
por: Li, Xiao, et al.
Publicado: (2018)

Value of HE4 Combined with Cancer Antigen 125 in the Diagnosis of Endometrial Cancer
por: Dong, Chunhua, et al.
Publicado: (2017)

Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis
por: Bie, Yachun, et al.
Publicado: (2014)

Pir2/Rnf144b is a potential endometrial cancer biomarker that promotes cell proliferation
por: Zhou, Qing, et al.
Publicado: (2018)

HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines
por: Li, Jinping, et al.
Publicado: (2013)

Clinical importance of serum HE4 and MMP2 levels in endometrial cancer patients
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2017)

Comprehensive Library Generation for Identification and Quantification of Endometrial Cancer Protein Biomarkers in Cervico-Vaginal Fluid
por: Njoku, Kelechi, et al.
Publicado: (2021)

Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients
por: Bignotti, E, et al.
Publicado: (2011)

Prevention Strategies in Endometrial Carcinoma
por: MacKintosh, Michelle L., et al.
Publicado: (2018)

Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance
por: Brennan, Donal J, et al.
Publicado: (2015)

HE4 Tissue Expression as A Putative Prognostic Marker in Low-Risk/Low-Grade Endometrioid Endometrial Cancer: A Review
por: Mais, Valerio, et al.
Publicado: (2022)

Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer
por: Chovanec, Josef, et al.
Publicado: (2017)

Optimization of Window Study Endpoints in Endometrial Cancer
por: Kitson, Sarah J., et al.
Publicado: (2019)

Polygenic risk score opportunities for early detection and prevention strategies in endometrial cancer
por: O’Mara, Tracy A., et al.
Publicado: (2020)

Can the Determination of HE4 and CA125 Markers Affect the Treatment of Patients with Endometrial Cancer?
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2021)

HE4 Transcription- and Splice Variants-Specific Expression in Endometrial Cancer and Correlation with Patient Survival
por: Jiang, Shi-Wen, et al.
Publicado: (2013)

Identification and characterization of endometrial carcinoma with tumor markers HE4 and CA125 in serum and endometrial tissue samples
por: Cuesta-Guardiola, Tatiana, et al.
Publicado: (2021)

Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review
por: Dochez, Vincent, et al.
Publicado: (2019)

Impact of Type 2 Diabetes Mellitus on Endometrial Cancer Survival: A Prospective Database Analysis
por: Njoku, Kelechi, et al.
Publicado: (2022)

Monocarboxylate Transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer
por: Latif, Ayşe, et al.
Publicado: (2017)

CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis
por: Behrouzi, Roya, et al.
Publicado: (2023)

Role of Human Epididymis Protein 4 (HE4) in Determining Survival of Patients With Endometrial Cancer: A Meta-Analysis
por: He, Ying, et al.
Publicado: (2020)

Diagnostic and Prognostic Values of Serum EpCAM, TGM2, and HE4 Levels in Endometrial Cancer
por: Lan, Ting, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u963keadic7i5seoveq8e48r7t